

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



PROSTEN HEALTH HOLDINGS LIMITED

長達健康控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 8026)

(1) PROPOSED CHANGE OF COMPANY NAME

(2) APPOINTMENT OF DIRECTOR AND CHIEF EXECUTIVE OFFICER

AND

(3) CHANGES IN COMPOSITION OF THE BOARD COMMITTEES

PROPOSED CHANGE OF COMPANY NAME

The Board proposes to change the English name of the Company from “Prosten Health Holdings Limited” to “China Brilliant Global Limited”, and to adopt the Chinese name of “朗華國際集團有限公司” as the dual foreign name of the Company in place of its existing Chinese name “長達健康控股有限公司”.

The proposed Change of Company Name is subject to the fulfillment of the conditions as set out in the paragraph headed “Conditions of the Change of Company Name” in this announcement.

A circular containing, among other matters, details of the proposed Change of Company Name, together with a notice of the EGM and the related form of proxy, will be despatched to the Shareholders in due course.

The Board of the Company hereby announces that the following changes with effect from 18 May 2018:

1. Ms. Chung will be appointed as an executive Director, a chief executive officer and a member of both the Nomination Committee and the Remuneration Committee of the Company;
2. cessation of Ms. Zhang Chunping as a member of both the Nomination Committee and the Remuneration Committee of the Company.

PROPOSED CHANGE OF COMPANY NAME

The board (the “**Board**”) of directors (the “**Director(s)**”) of Prosten Health Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) proposes to change the English name of the Company from “Prosten Health Holdings Limited” to “China Brilliant Global Limited”, and to adopt the Chinese name of “朗華國際集團有限公司” as the dual foreign name of the Company in place of its existing Chinese name “長達健康控股有限公司” (the “**Change of Company Name**”).

A special resolution will be proposed at an extraordinary general meeting (the “**EGM**”) of the Company to be convened for the shareholders (the “**Shareholders**”) of the Company to consider and, if thought fit, to approve the proposed Change of Company Name.

CONDITIONS FOR THE PROPOSED CHANGE OF COMPANY NAME

The proposed Change of Company Name is conditional upon the following conditions having been satisfied:

- (i) the passing of a special resolution by the Shareholders approving the Change of Company Name at the EGM; and
- (ii) the Registrar of Companies in the Cayman Islands granting approval for the Change of Company Name.

Subject to the satisfaction of the conditions set out above, the Change of Company Name will take effect from the date on which the Registrar of Companies in the Cayman Islands enters the new English name and dual foreign name in Chinese of the Company on the register of companies in place of the former English and dual foreign name in Chinese of the Company and issues a certificate of incorporation on change of name. The Company will then carry out all necessary filing procedures with the Companies Registry in Hong Kong.

REASONS FOR THE PROPOSED CHANGE OF COMPANY NAME

In order to enhance the long-term growth potential of the Group, the Company has formulated long-term business strategy to explore other business or investment opportunities and broaden its scope of business. The Board is of the view that a change of company name will help establish a fresh corporate image identity and better reflect the Group’s future business plans and development. As such, the Board considers that the Proposed Change of Company Name is in the best interests of the Company and its Shareholders as a whole.

EFFECTS OF THE PROPOSED CHANGE OF COMPANY NAME

The proposed Change of Company Name will not affect any rights of the Shareholders or the Company’s daily operations or its financial position. Once the Change of Company Name has become effective, any new share certificates of the Company issued thereafter will bear the new name of the Company. However, all the existing share certificates in issue bearing the present name of the Company will, after the proposed Change of Company Name has become effective, continue to be effective and as documents of title to the shares of the Company, will continue to be valid for trading, settlement, registration and delivery purposes. Accordingly, there will not be any arrangement for free exchange of the existing share certificates of the Company for new share certificates bearing the new name of the Company.

In addition, subject to the confirmation by the Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”), the English and Chinese stock short names of the Company for trading in the securities on the Stock Exchange will also be changed after the Change of Company Name becoming effective.

APPOINTMENT OF EXECUTIVE DIRECTOR AND CHIEF EXECUTIVE OFFICER

The Board further announces that with effect from 18 May 2018, Ms. Chung, Elizabeth Ching Yee (“**Ms. Chung**”) is appointed as an executive Director and a chief executive officer of the Company under the Rules (the “**GEM Listing Rules**”) Governing the Listing of Securities on the Growth Enterprise Market (“**GEM**”) of the Hong Kong Stock Exchange Limited.

The biography of Ms. Chung is set out below:

Ms. Chung, age 47, has extensive professional experience in Global brand building and investment advisory. She is appointed as CEO and executive director of Paganini Milano (SG) PTE Limited in early 2017, responsible for brand positioning, strategic planning, and business development. She leads her team to develop retail business globally. Prior to that, Ms. Chung was a director at BOCI Securities Limited and an assistant vice president at HSBC Broking Securities (Asia) Limited responsible for investment advisory for over 10 years. Ms. Chung graduated at Rutgers University, and started her professional career at General Electric Capital Corporation in the United States of America and she joined A.T. Kearney (Hong Kong) Limited after returning Hong Kong.

Ms. Chung has not been a director of any public company, the securities of which are listed on any securities market in Hong Kong or overseas during the three years immediately preceding the date of this appointment.

As at the date of this announcement, Ms. Chung does not have, and is not deemed to have any interests or short positions in any shares, underlying shares or debentures of the Company or any of its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). Ms. Chung is not connected with any other Directors, senior management, substantial shareholders or controlling shareholders (as defined under the GEM Listing Rules) of the Company.

The Company has entered into a service agreement with Ms. Chung for 3 years in respect of her appointment which will continue until terminated by either party giving to the other party not less than three months’ notice in writing subject to the retirement and re-election requirements in accordance with the articles of association of the Company. Pursuant to the terms of the service agreement, Ms. Chung will receive a director’s fee of HK\$1,200,000 per annum with reference to her duties and responsibilities in the Company, comparable market statistics and the recommendation from the nomination and remuneration committee of the Company.

Save as disclosed above, there are no information to be disclosed pursuant to any of the requirements of Rule 17.50(2) of the GEM Listing Rules (particularly in relation to subparagraphs (h) to (v) therein) nor are there other matters that need to be brought to the attention of the Shareholders relating to the appointment of Ms. Chung.

The Board would like to take this opportunity to extend its welcome to Ms. Chung on her new appointments.

CHANGES IN COMPOSITION OF THE BOARD COMMITTEES

Ms. Chung will be appointed as a member of both the Nomination Committee and the Remuneration Committee of the Company with effect from 18 May 2018.

Ms. Zhang Chunping will cease to be a member of the Nomination Committee and the Remuneration Committee of the Company with effect from 18 May 2018.

GENERAL

A circular containing, among other matters, details of the proposed Change of Company Name, together with a notice of the EGM and the related form of proxy, will be despatched to the Shareholders as soon as practicable. Further announcement(s) relating to the effective date of the Change of Company Name and the corresponding change in, among others, the stock short names of the shares of the Company will be made by the Company as and when appropriate.

By Order of the Board
PROSTEN HEALTH HOLDINGS LIMITED
Zhang Chunhua
Chairman

Hong Kong, 2 May 2018

As at the date of this announcement, the Board comprises the following directors:

Mr. Zhang Chunhua (Executive Director and Chairman)
Ms. Zhang Chunping (Executive Director)
Mr. Xu Zhigang (Non-executive Director)
Ms. Chan Mei Yan Hidy (Independent Non-executive Director)
Mr. Kwan Chi Hong (Independent Non-executive Director)
Ms. Lee Kwun Ling, May Jean (Independent Non-executive Director)

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the GEM website at www.hkgem.com on the “Latest Company Announcements” page for at least 7 days from the date of its posting and the Company’s website at www.prosten.com.